Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
de la Cruz-Merino, L.
1547  Ergebnisse:
Personensuche X
?
1

Overall survival from tebentafusp versus nivolumab plus ipi..:

Piulats, J.M. ; Watkins, C. ; Costa-García, M....
Annals of Oncology.  35 (2024)  3 - p. 317-326 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Updated overall survival from the MONALEESA-3 trial in post..:

Neven, P. ; Fasching, P. A. ; Chia, S....
Breast Cancer Research.  25 (2023)  1 - p. , 2023
Link: https://doi.org/10.1186/..
 
?
3

Randomized phase II study of fulvestrant plus palbociclib o..:

Albanell, J. ; Martínez, M.T. ; Ramos, M....
European Journal of Cancer.  161 (2022)  - p. 26-37 , 2022
Link: https://doi.org/10.1016/..
 
?
4

Pembrolizumab in combination with gemcitabine for patients ..:

de la Cruz-Merino, L. ; Gion, M. ; Cruz, J....
BMC Cancer.  22 (2022)  1 - p. , 2022
Link: https://doi.org/10.1186/..
 
?
5

The complexity of cancer immunotherapy illustrated through ..:

Vieco-Martí, I. ; López-Carrasco, A. ; de la Cruz-Merino, L...
The International Journal of Biological Markers.  37 (2022)  2 - p. 113-122 , 2022
Link: https://doi.org/10.1177/..
 
?
6

Corrigendum to 'Ribociclib plus fulvestrant for postmenopau..:

Slamon, D.J. ; Neven, P. ; Chia, S....
Annals of Oncology.  32 (2021)  10 - p. 1307 , 2021
Link: https://doi.org/10.1016/..
 
?
7

SEOM clinical guideline for the management of cutaneous mel..:

Majem, M. ; Manzano, J. L. ; Marquez-Rodas, I....
Clinical and Translational Oncology.  23 (2021)  5 - p. 948-960 , 2021
Link: https://doi.org/10.1007/..
 
?
8

Ribociclib plus fulvestrant for postmenopausal women with h..:

Slamon, D.J. ; Neven, P. ; Chia, S....
Annals of Oncology.  32 (2021)  8 - p. 1015-1024 , 2021
Link: https://doi.org/10.1016/..
 
?
9

SEOM clinical guideline for the management of immune-relate..:

Majem, M. ; García-Martínez, E. ; Martinez, M....
Clinical and Translational Oncology.  22 (2020)  2 - p. 213-222 , 2020
Link: https://doi.org/10.1007/..
 
?
10

Impact of intestinal dysbiosis-related drugs on the efficac..:

Pérez-Ruiz, E. ; Jiménez-Castro, J. ; Berciano-Guerrero, M.-A....
Clinical and Translational Oncology.  22 (2020)  10 - p. 1778-1785 , 2020
Link: https://doi.org/10.1007/..
 
?
11

New horizons in breast cancer: the promise of immunotherapy:

GEICAM (Spanish Breast Cancer Research Group) and GÉTICA (Spanish Group for Cancer Immuno-Biotherapy) ; de la Cruz-Merino, L. ; Palazón-Carrión, N....
Clinical and Translational Oncology.  21 (2018)  2 - p. 117-125 , 2018
Link: https://doi.org/10.1007/..
 
?
12

2018 consensus statement by the Spanish Society of Patholog..:

Losa, F. ; Iglesias, L. ; Pané, M....
Clinical and Translational Oncology.  20 (2018)  11 - p. 1361-1372 , 2018
Link: https://doi.org/10.1007/..
 
?
13

nab-Paclitaxel plus carboplatin or gemcitabine versus gemci..:

Yardley, D.A. ; Coleman, R. ; Conte, P....
Annals of Oncology.  29 (2018)  8 - p. 1763-1770 , 2018
Link: https://doi.org/10.1093/..
 
?
14

Nuevos avances de tratamiento inmunobiológico en el melanom..:

Pérez Gago, M.C. ; Saavedra Santa Gadea, O. ; de la Cruz-Merino, L.
Actas Dermo-Sifiliográficas.  108 (2017)  8 - p. 721-728 , 2017
Link: https://doi.org/10.1016/..
 
?
15

Advances in the Immunobiological Therapies for Advanced Mel..:

Gago, M.C. Pérez ; Gadea, O. Saavedra Santa ; de la Cruz-Merino, L.
Actas Dermo-Sifiliográficas (English Edition).  108 (2017)  8 - p. 721-728 , 2017
Link: https://doi.org/10.1016/..
 
1-15